Olverembatinib (HQP1351) in Combination with Lisaftoclax Overcomes Venetoclax Resistance in Preclinical Model of Acute Myeloid Leukemia (AML)

被引：0

作者：

Xiong, Yan ^{[1
]}

Liang, Zhiyan ^{[2
]}

Min, Ping ^{[1
]}

Wu, Bingxing ^{[1
]}

Yu, Huidan ^{[1
]}

Yang, Dajun ^{[1
,2
,3
]}

Zhai, Yifan ^{[1
,2
]}

机构：

[1] Ascentage Pharm Suzhou Co Ltd, Suzhou, Peoples R China

[2] Ascentage Pharm Grp Inc, Rockville, MD USA

[3] Sun Yat sen Univ, Collaborat Innovat Ctr Canc Med, Dept Expt Res, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-202699

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：5777 / 5778

页数：2

共 50 条

[41] Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia
Bosc, Claudie
Saland, Estelle
Bousard, Aurelie
Gadaud, Noemie
Sabatier, Marie
Cognet, Guillaume
Farge, Thomas
Boet, Emeline
Gotanegre, Mathilde
Aroua, Nesrine
Mouchel, Pierre-Luc
Polley, Nathaniel
Larrue, Clement
Kaphan, Eleonore
Picard, Muriel
Sahal, Ambrine
Jarrou, Latifa
Tosolini, Marie
Rambow, Florian
Cabon, Florence
Nicot, Nathalie
Poillet-Perez, Laura
Wang, Yujue
Su, Xiaoyang
Fovez, Quentin
Kluza, Jerome
Arguello, Rafael Jose
Mazzotti, Celine
Avet-Loiseau, Herve
Vergez, Francois
Tamburini, Jerome
Fournie, Jean-Jacques
Tiong, Ing S.
Wei, Andrew H.
Kaoma, Tony
Marine, Jean-Christophe
Recher, Christian
Stuani, Lucille
Joffre, Carine
Sarry, Jean-Emmanuel
NATURE CANCER, 2021, 2 (11) : 1204 - +
[42] Preclinical Studies and Phase II Trial of Venetoclax in Combination with Chidamide and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia
Zha, Jie
Zhou, Hui
Zhong, Mengya
Wang, Ying
Du, Xin
Gong, Tiejun
Lin, Zhijuan
Cai, Yun
Xie, Siting
Xie, Chendi
Feng, XianQi
Huang, ZhenQi
Su, Liping
Luo, Jianmin
Yang, Lin
Li, Zhenling
Chen, Bi-yun
Xie, Ying
Zhu, Yu
Shi, Pengcheng
Li, Zhifeng
Jiang, Yirong
Xu, Bing
BLOOD, 2022, 140 : 3292 - 3293
[43] The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia
Lim, Byungho
Yoo, Dabin
Chun, Younghwa
Go, Areum
Cho, Kyung-Jin
Choi, Daeun
Jung, Myoung Eun
Lee, Ha Young
Boohaker, Rebecca J.
Lee, Jin Soo
Jung, DooYoung
Choi, Gildon
BLOOD CANCER JOURNAL, 2022, 12 (04)
[44] Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials
Jiang, Qian
Huang, Xiaojun
Chen, Zi
Niu, Qian
Shi, Dayu
Li, Zongru
Hou, Yue
Hu, Yu
Li, Weiming
Liu, Xiaoli
Xu, Na
Song, Yongping
Zhang, Yanli
Meng, Li
Hong, Zhenya
Liu, Bingcheng
Zeng, Shan
Men, Lichuang
Li, Yan
Chen, Suning
Xue, Mengxing
Zhu, Huanling
Li, He
Du, Xin
Lou, Jin
Zhang, Xiaohan
Liang, Yang
Dai, Yujun
Lu, Ming
Wang, Hengbang
Ji, Jiao
Yue, Changai
Yang, Dajun
Zhai, Yifan
BLOOD, 2020, 136
[45] The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia
Byungho Lim
Dabin Yoo
Younghwa Chun
Areum Go
Kyung-Jin Cho
Daeun Choi
Myoung Eun Jung
Ha Young Lee
Rebecca J. Boohaker
Jin Soo Lee
DooYoung Jung
Gildon Choi
Blood Cancer Journal, 12
[46] ERK1/2 Inhibition Overcomes Resistance in Acute Myeloid Leukemia (AML) and Alters Mitochondrial Dynamics
Sharma, Priyanka
Piya, Sujan
Ma, Huaxian
Baran, Natalia
Zal, Malgorzata Anna
Hindley, Christopher J.
Dao, Kim-Hien
Sims, Martin
Zal, Tomasz
Ruvolo, Vivian
Andreeff, Michael
Borthakur, Gautam
BLOOD, 2021, 138
[47] Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study
Jiang, Qian
Li, Zongru
Zhang, Gongli
Hu, Yu
Li, Weiming
Song, Yongping
Li, Junmin
Zhou, Li
Liu, Bingcheng
Liu, Xiaoli
Xu, Na
Chen, Suning
Liu, Zhenfang
Zhu, Huanling
Jin, Jie
Huang, He
Qian, Sixuan
Meng, Li
Du, Xin
Zhao, Xielan
Gao, Sujun
Liang, Yang
Hou, Ming
Wang, Wei
Chen, Zi
Niu, Qian
Men, Lichuang
Yang, Dajun
Zhai, Yifan
Huang, Xiaojun
BLOOD, 2023, 142
[48] Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 113, 2022)
Jiang, Qian
Li, Zongru
Qin, Yazhen
Li, Weiming
Xu, Na
Liu, Bingcheng
Zhang, Yanli
Meng, Li
Zhu, Huanling
Du, Xin
Chen, Suning
Liang, Yang
Hu, Yu
Liu, Xiaoli
Song, Yongping
Men, Lichuang
Chen, Zi
Niu, Qian
Wang, Hengbang
Lu, Ming
Yang, Dajun
Zhai, Yifan
Huang, Xiaojun
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
[49] AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3- ITD acute myeloid leukemia
Post, Sean M.
Ma, Huaxian
Malaney, Prerna
Zhang, Xiaorui
Aitken, Marisa J. L.
Mak, Po Yee
Ruvolo, Vivian R.
Yasuhiro, Tomoko
Kozaki, Ryohei
Chan, Lauren E.
Ostermann, Lauren B.
Konopleva, Marina
Carter, Bing Z.
DiNardo, Courtney
Andreeff, Michael D.
Khoury, Joseph D.
Ruvolo, Peter P.
HAEMATOLOGICA, 2022, 107 (06) : 1311 - 1322
[50] Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 159, 2022)
Jiang, Qian
Li, Zongru
Qin, Yazhen
Li, Weiming
Xu, Na
Liu, Bingcheng
Zhang, Yanli
Meng, Li
Zhu, Huanling
Du, Xin
Chen, Suning
Liang, Yang
Hu, Yu
Liu, Xiaoli
Song, Yongping
Men, Lichuang
Chen, Zi
Niu, Qian
Wang, Hengbang
Lu, Ming
Yang, Dajun
Zhai, Yifan
Huang, Xiaojun
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)

← 1 2 3 4 5 →